Harvard Apparatus withdraws IPO, plans NASDAQ listing via Harvard Bioscience spinoff

Comment

Shutterstock photo

Harvard Apparatus Regenerative Technology, a Harvard Bioscience carve-out focusing on regenerative medicine, withdrew its plans for an initial public offering on Thursday citing poor market conditions. Instead, Harvard Bioscience plans to spin off 100% of Harvard Apparatus Regenerative Technology's common stock to its existing shareholders. The company will list on the NASDAQ under the symbol HART.

The Holliston, MA-based company, which was founded in 2009, set terms for a $19 million IPO in March. Summer Street Research Partners and Maxim Group were set to be the joint bookrunners on the deal.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.



This article appears in: News Headlines , IPOs


More from Renaissance Capital

Subscribe






Renaissance Capital
Contributor:

Renaissance Capital

IPOs
Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com